Durvalumab in Small Cell Lung Cancer: Insights from the ADRIATIC Trial

The ADRIATIC trial shows durvalumab maintenance after definitive chemoradiation significantly extends overall survival in limited‑stage small cell lung cancer, with median overall survival of 66.1 months in the durvalumab arm.

The survival benefit was observed in patients who had completed chemoradiation and received durvalumab as planned maintenance. Progression‑free survival was also prolonged, reinforcing durable disease control with checkpoint blockade.

Safety findings were consistent with known PD‑L1 blockade effects: immune‑related adverse events occurred as expected, severe (grade 3–4) toxicities were uncommon, and no new safety signals emerged in the maintenance setting.